References
- Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976;2:1403.
- Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408–414.
- Talesa VN. Acetylcholinesterase in Alzheimer’s disease. Mech Ageing Dev 2001;122:1961–1969.
- Medications for Alzheimer’s disease. Benefits of currently approved drugs are limited, but research continues. Harv Ment Health Lett 2011; 27: 4–5.
- Doody RS, Cummings JL, Farlow MR. Reviewing the Role of Donepezil in the Treatment of Alzheimer’s Disease. Curr Alzheimer Res 2011; DOI: 10.2174/1567212221756532050
- Weintraub D, Somogyi M, Meng X. Rivastigmine in Alzheimer’s disease and Parkinson’s disease dementia: an ADAS-cog factor analysis. Am J Alzheimers Dis Other Demen 2011;26:443–449.
- Wallin AK, Wattmo C, Minthon L. Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting. Neuropsychiatr Dis Treat 2011;7:565–576.
- Bosak A, Katalinic M, Kovarik Z. [Cholinesterases: structure, role, and inhibition]. Arh Hig Rada Toksikol 2011;62:175–190.
- Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol 2003;2:539–547.
- Liu A, Guang H, Zhu L, Du G, Lee SM, Wang Y. 3D-QSAR analysis of a new type of acetylcholinesterase inhibitors. Sci China, C, Life Sci 2007;50:726–730.
- Akula N, Lecanu L, Greeson J, Papadopoulos V. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA. Bioorg Med Chem Lett 2006;16:6277–6280.
- De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry 2001;40:10447–10457.
- Bartolini M, Bertucci C, Cavrini V, Andrisano V. β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 2003;65:407–416.
- Mesulam MM, Asuncion Morán M. Cholinesterases within neurofibrillary tangles related to age and Alzheimer’s disease. Ann Neurol 1987;22:223–228.
- Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007;69:1622–1634.
- Liston DR, Nielsen JA, Villalobos A, Chapin D, Jones SB, Hubbard ST et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer’s disease. Eur J Pharmacol 2004;486:9–17.
- Cerbai F, Giovannini MG, Melani C, Enz A, Pepeu G. N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine. Eur J Pharmacol 2007;572:142–150.
- Rydberg EH, Brumshtein B, Greenblatt HM, Wong DM, Shaya D, Williams LD et al. Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: Binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge. J Med Chem 2006;49:5491–5500.
- Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008;51:347–372.
- Cavalli A, Bolognesi ML, Capsoni S, Andrisano V, Bartolini M, Margotti E et al. A small molecule targeting the multifactorial nature of Alzheimer’s disease. Angew Chem Int Ed Engl 2007;46:3689–3692.
- Skovronsky DM, Lee VM, Trojanowski JQ. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 2006;1:151–170.
- Wang B, Mai YC, Li Y, Hou JQ, Huang SL, Ou TM et al. Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem 2010;45:1415–1423.
- Hermecz I, Kökösi J, Podányi B, Szász G. Synthesis of Indolyl-4(3H)-Quinazolinones. Heterocycles 1994;37:903–914.
- Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
- Decker M. Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine. Eur J Med Chem 2005;40:305–313.
- Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK and Olson AJ. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 1998;19:1639–1662.
- Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des 2010;24:417–422.